KADAR FERITIN SETELAH PEMBERIAN TERAPI KELASI BESI DEFERASIROX DIBANDINGKAN DENGAN DEFERIPRONE PADA PASIEN THALASEMIA BETA MAYOR DI RSU HERMINA JATINEGARA

Fiska Maulina Putri, . (2024) KADAR FERITIN SETELAH PEMBERIAN TERAPI KELASI BESI DEFERASIROX DIBANDINGKAN DENGAN DEFERIPRONE PADA PASIEN THALASEMIA BETA MAYOR DI RSU HERMINA JATINEGARA. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.

[img] Text
ABSTRAK.pdf
Download (74kB)
[img] Text
AWAL.pdf
Download (1MB)
[img] Text
BAB I.pdf
Restricted to Repository UPNVJ Only
Download (207kB)
[img] Text
BAB II.pdf
Restricted to Repository UPNVJ Only
Download (755kB)
[img] Text
BAB III. pdf.pdf
Restricted to Repository UPNVJ Only
Download (223kB)
[img] Text
BAB IV.pdf
Restricted to Repository UPNVJ Only
Download (220kB)
[img] Text
BAB V...pdf
Download (82kB)
[img] Text
DAFTAR PUSTAKA..pdf
Download (196kB)
[img] Text
RIWAYAT HIDUP.pdf
Restricted to Repository UPNVJ Only
Download (83kB)
[img] Text
LAMPIRAN..pdf
Restricted to Repository UPNVJ Only
Download (763kB)
[img] Text
HASIL PLAGIARISME.pdf
Restricted to Repository staff only
Download (10MB)
[img] Text
ARTIKEL KI.pdf
Restricted to Repository staff only
Download (316kB)

Abstract

Beta thalassemia major is a genetic disorder caused by the reduced (beta+) or absent (beta0) synthesis of the beta globin chains of hemoglobin, leading to a quantitative defect of hemoglobin synthesis. Thalassemia leads to iron overload due to regular blood transfusions, necessitating chelation therapy with agents such as deferasirox, deferoxamine, or deferiprone. This study aims to understand the characteristics of patients with beta thalassemia major, determine the mean reductions of serum ferritin levels with deferasirox and deferiprone therapies, and compare the ability of these two therapies in reducing ferritin levels at Hermina Jatinegara Hospital. Using a cross sectional design, this research involved 74 patients, with each therapy group consisting of 37 patients. Data were collected from medical records. The patient population predominantly comprised females (52.7%), adolescents (45.95%), and those who had received 21-30 transfusions (44.6%) from January 2023 to October 2024. This research evaluates the ferritin levels over a three-month therapy period. Ferritin levels were measured whenever they exceeded or same as 1000 ng/mL and reassessed after three months. The results indicated that deferasirox significantly reduced ferritin levels more than deferiprone, with mean reductions of -2108.61±1913.70 ng/mL (Mean±Std) and -983.64±948.06 ng/mL (Mean±Std), respectively. There was a significant difference in the reduction of ferritin levels between the deferasirox and deferiprone therapies. These findings suggest that deferasirox is more effective in managing iron overload in patients with beta thalassemia major. Further research is recommended to evaluate long-term outcomes and optimize treatment protocols.

Item Type: Thesis (Skripsi)
Additional Information: [No.Panggil: 2110211017] [Pembimbing 1 : Hany Yusmaini] [Pembimbing 2: Pritha Maya Savitri] [Penguji 1 : Citra Ayu Aprilia]
Uncontrolled Keywords: Beta Thalassemia Major, Deferasirox, Deferiprone, Iron Chelation Therapy, Ferritin
Subjects: R Medicine > R Medicine (General)
R Medicine > RM Therapeutics. Pharmacology
Divisions: Fakultas Kedokteran > Program Studi Kedokteran (S1)
Depositing User: FISKA MAULINA PUTRI
Date Deposited: 18 Mar 2025 01:21
Last Modified: 18 Mar 2025 01:21
URI: http://repository.upnvj.ac.id/id/eprint/34185

Actions (login required)

View Item View Item